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Abstract: Colorectal cancer (CRC) is one of the most common cancers worldwide, with high morbidity
and mortality rates. A number of factors including modulation of the tumor microenvironment, high
metastatic capability, and resistance to treatment have been associated with CRC disease progression.
Recent studies have documented that tumor-derived extracellular vesicles (EVs) play a significant
role in intercellular communication in CRC via transfer of cargo lipids, proteins, DNA and RNAs to
the recipient tumor cells. This transfer influences a number of immune-related pathways leading to
activation/differentiation/expression of immune cells and modulation of the tumor microenvironment
that plays a significant role in CRC progression, metastasis, and drug resistance. Furthermore,
tumor-derived EVs are secreted in large amounts in biological fluids of CRC patients and as such the
expression analysis of EV cargoes have been associated with prognosis or response to therapy and
may be a source of therapeutic targets. This review aims to provide a comprehensive insight into the
role of EVs in the modulation of the tumor microenvironment and its effects on CRC progression,
metastasis, and drug resistance. On the other hand, the potential role of CRC derived EVs as a source
of biomarkers of response and therapeutic targets will be discussed in detail to understand the
dynamic role of EVs in CRC diagnosis, treatment, and management.
Keywords: colorectal cancer; extracellular vesicles; tumor microenvironment; metastasis; drug
resistance; miRNA; biomarker
1. Introduction
Colorectal cancer (CRC) is the third most common cancer globally, with high morbidity and
mortality rates. Worldwide, approximately 9% of all cancer incidence and 8% of all cancer deaths
have been attributed to CRC, with approximately 1.2 million new CRC cases diagnosed per year [1,2].
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The incidence of CRC has been reported to be highest in developed countries, including Australia,
New Zealand, Canada, the United States and parts of Europe [3].
The natural course of CRC development involves alterations due to well-defined histopathological
changes (adenoma-carcinoma sequence) that initiate tumor development leading to tumor progression.
According to the American Joint Committee on Cancer (AJCC), CRC has been grouped into four
distinct stages of transition. In stage I, CRC cells are actively proliferating, forming small, benign
polyps. A small fraction of these polyps accumulates various somatic mutations over time leading to
the transformation of benign polyps into malignant types, thus transitioning into stage II. In stage
III, the tumors cells gradually increase in number, accumulating further mutations with the invasion
of the surrounding muscle wall of the colon. Finally, in stage IV, these cancer cells accomplish the
capability to metastasize through the blood and the lymphatic system to other organs. However,
modulation of the tumor microenvironment/immunological pathways in the tumor landscape has also
been associated to play a significant role in CRC development [4].
The main options for CRC treatment include surgery and chemotherapy, depending mainly on
the CRC stage and the location of the polyps [5]. Substantial advancements have been made in the
treatment and management of CRC, mainly through the administration of adjuvant chemotherapy
agents like fluorouracil and oxaliplatin [6]. Unfortunately, until now, the success rate of chemotherapy
in CRC is only 30% [7,8]. Though the treatment modalities in CRC have advanced considerably
in recent years, the main challenge that clinicians continue to endure is drug resistance that serves
as an impediment for CRC management [9]. On the other hand, survival rates in CRC depend
largely on the stage at which disease is diagnosed, with 5-year survival rates observed to range
from approximately 90% for stage I to 10% for stage IV disease [2]. Thus, the earlier the diagnosis,
the higher the chance of survival, indicating that diagnostic/prognostic biomarkers may play in
prominent role in efficient screening and management of CRC [4]. Recently, studies have demonstrated
that tumor cells secrete membrane-bound vesicles, called extracellular vesicles (EVs), that serve
as efficient mediators of intercellular communication [10] by releasing large amounts of nucleic
acids, cytokines/chemokines, angiogenic factors, extracellular matrix remodeling factors as well
as tumor microenvironment modulating factors during carcinogenesis [11–13]. Studies have also
documented that cargoes transferred through EVs can alter the functions and phenotypes of recipient
cells [14,15]. In CRC, this is important as these alterations can affect the regulation of multiple cellular
processes [16], lead to modulation of the tumor microenvironment and enhance tumor cell proliferation
and transformation [14,15]. On the other hand, in addition to exerting cellular changes, EVs are
secreted abundantly in body fluids such as plasma, serum, saliva, urine, cerebrospinal fluid (CSF),
breast milk, bile, broncho-alveoler lavage fluid, and malignant ascites. It is well perceived that due to
these intrinsic properties, CRC-derived EVs are being actively explored as a potential source of new
prognostic/diagnostic biomarkers [17].
The main aim of this review is to focus on the role of EVs in CRC with respect to immune
modulation, drug resistance, and metastasis, as well as to review the literature regarding EVs as
a potential source of therapeutic targets in CRC.
2. EVs and Colorectal Cancer
According to the MISEV2018 guidelines, extracellular vesicles (EVs), is a collective term covering
subtypes of cell-released, membranous nanometre-sized structures that are classified into various
subpopulations based on size, biogenesis and cell origin or function [18]. Based on sizes, EV
subpopulations include nanovesicles, microvesicles, virus-like particles, exosome-like vesicles, and
microparticles, while on the basis of biogenesis, exosomes, membrane particles, outer membrane
vesicles, and shedding membrane vesicles are considered important subpopulations. Furthermore,
platelet-dust, oncosomes, matrix-vesicles, ectosomes, dexosomes, texosomes, epididymosomes,
cardiosomes, prostasomes, rhinosomes, apoptotic bodies, and tolerosomes are another set of
subpopulations that are described on the basis of cell origin or function. However, with this exceptional
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diversity in EV subpopulations, it has been reported that even further subpopulations within these
subpopulations can be defined, based on vesicle size, density, RNA, protein, and DNA cargo, as well
as morphology [19]. For the sake of clarity in this review, we will consider the following EV subtypes
for the purpose of discussion: (a) Small EVs, 30–150 nm in size, secreted via a multivesicular-body
endocytic process and designated as exosomes; and (b) microvesicles, 100–1000 nm in size, formed via
outward budding of the plasma membrane [20,21].
Comparison of small EVs/exosomes with microvesicles has shown that small EVs/exosomes are
more homogenous with respect to size and molecular composition. However, due to the differences in
the origin, the mechanism of formation and release, exosomes and microparticles often have differences
in the levels of cargo proteins [19]. Due to the variances in isolation methods and characterization
protocols used by researchers, it is very difficult to pinpoint a single cargo content that can clearly
distinguish exosomes and microvesicles [22]. Since both the exosomes and microvesicles are membrane
covered particles released by the cells to facilitate intracellular communication and have a key role in
several pathological conditions, they are combined under the family of extracellular vesicles.
Structurally, the phospholipid bilayer of EVs is composed mainly of lipids, including ceramide,
cholesterol, sphingomyelin, phosphoglycerides, glycosphingolipids, phosphatidyl serine (PS),
phosphatidylethanolamine, mannose, N-linked glycans, polylactosamine and sialic acid [13]. Studies
have reported that there are a number of proteins that originate from the cytosol or endosomal
compartments along with a few proteins from plasma membrane in EVs that are considered as potential
markers for EV sub-populations. These include tetraspanins (CD9, CD63, CD81 and CD82), 14-3-3
proteins, major histocompatibility complex (MHC) molecules and cytosolic proteins such as heat
shock proteins, Tsg101 and the Endosomal Sorting Complex Required for Transport (ESCRT-3) binding
protein Alix, Rab GTPases, SNARE, flotillins, Annexin, Clathrin, and platelet-derived growth factor
receptors, etc. [23].
Studies have reported that EVs are produced in high quantities by rapidly growing cells including
B-lymphocytes, dendritic cells, cytotoxic T cells, platelets, mast cells, neurons, oligo-dendrocytes,
Schwann cells and intestinal epithelial cells [24]. Therefore, an increase in the amount and alterations
in the expression of EV cargoes are widely reported to indicate pathological conditions, including
cancers [16]. This is evidenced by studies that have shown that tumor cell-derived EVs promote cancer
progression and invasion by various mechanisms. A study on the highly malignant melanoma cell
line, B16-10, and poorly metastatic F1 melanoma cell lines showed that the EVs secreted by malignant
melanoma cells were able to transfer their metastatic ability efficiently to poorly metastatic tumor
cells, indicating that EVs can induce phenotypic changes to enhance the metastatic capabilities of
tumor cells [25]. On the other hand, EVs have also been associated with incurring an anti-tumor
potential, e.g., NK cells derived EVs containing both perforin and CD95L, have been reported to
express anti-melanoma activity both in vitro and in vivo [26]. Similarly, dendritic cell-derived EVs
(Dex), loaded with MHC class I and II-restricted cancer antigens, have been reported to serve as
effective maintenance therapy in non-small cell lung cancer (NSCLC) via boosting of natural killer
(NK) cell arm of antitumor immunity [27].
In CRC, the role of EVs in tumor development and proliferation has been studied extensively
with interesting results. A study on HT29-19, a permanently differentiated clone of human colorectal
adenocarcinoma cell line HT29, has reported that EVs secreted by HT29-19, from apical and basolateral
sides show distinct morphological features [28]. The EVs secreted from the apical sides were found to
be homogenous, with approximately three-fold higher protein content per million cells than the EVs
secreted from the basolateral side. In comparison, the EVs secreted by the basolateral side were found
to be often aggregated with heterogeneous size and shape. Irrespective of secretion from the apical
and basolateral sides, the secreted EVs were found to contain MHC class I molecules, CD26/dipeptidyl
peptidase IV (DPPIV), CD63 and CD26 [28]. This finding is significant as it provides an insight that the
secreted EVs may carry accessory molecules involved in antigen presentation and thus can modulate
the immune cells independent of direct cellular contact with effector cells [28]. Similarly, a study on EVs
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isolated from culture supernatants of CRC cell line SW403 and peripheral blood of CRC patients were
both found to contain Fas ligand and TRAIL on their membrane with CD63, HLA class I molecule and
carcinoembryonic antigen (CEA) as its cargo proteins. On the other hand, EVs derived from peripheral
blood of healthy controls did not express any of these proteins, indicating that CRC derived EVs are
independently capable of inducing apoptosis in activated T-cells through Fas ligand and TRAIL [29].
EVs produced by CRC cell lines have also been reported to induce proliferation, migratory
capacity, and invasiveness. For example, EVs secreted by CRC cell line, SW480, have been reported to
express CEA, CD81 and TSG101, which has been documented to induce manifestations of tumor-like
phenotypes, morphological changes, spheroid formation and localization of plasma membrane vacuolar
H+-ATPase [30]. Likewise, human colon adenocarcinoma cell line, HCA-7, has also been reported
to release EVs containing EGFR ligands-heparin-binding EGF-like growth factor (HB-EGF) and
amphiregulin, that can lead to enhanced invasiveness in tumor cells [31]. Similar studies on the
metastatic potential of EVs have been done with interesting results, e.g., study on human colorectal
cancer cell lines, HCT-15, SW480, and WiDr, has reported that EVs secreted by these cell lines contain
mRNAs (CD81), microRNAs (miR-21, miR-192, and miR-221), and natural antisense RNAs (LRRC24,
MDM2 and CDKN1A genes) that are delivered into human hepatocellular carcinoma cell line HepG2
and human lung cancer cell line A549. The results from this study are relevant, as they reveal the
capability of EVs to shuttle between cells and play a vital role in gene regulation and expression
inducing a metastasis potential in recipient cells [32]. Furthermore, a study on CRC specific cell lines,
SW480, has documented that SW480 derived EVs are efficiently transferred to HepG2 cells via dynamin
and clathrin-dependent endocytosis leading to activation of mitogen-activated protein kinase pathway
thus enhancing cell migration in the target cells [33].
Published literature on CRC EVs has documented that these EVs can induce bidirectional
interactions among tumor and tumor-associated cells via modulation of the tumor microenvironment.
Details on modulation of tumor microenvironment in CRC and the role of EVs are discussed in
detail below.
3. Components of the Tumor Microenvironment in CRC
CRC is a highly heterogeneous disease that exhibits differences in its biological, clinical and
physiologic functions. The major players in CRC development and progression include somatic
changes induced by genetic and epigenetic mutations that allow cancerous cells to attain features
required for survival and unrestrained proliferation [34]. In addition to these genetic alterations,
a critical biological feature of CRC, that serves as a contributor to sustained growth and invasion is the
‘tumor microenvironment’ [35]. The tumor microenvironment (TME) by definition is an interactive
surrounding cellular environment around the tumor comprising of blood vessels, immune cells,
inflammatory cells, lymphocytes, signaling molecules, fibroblasts, bone marrow-derived and the
extracellular matrix (ECM) [36]. The main function of TME is to establish a cellular communication
pathway with diverse capacities to induce beneficial consequences for tumorigenesis such as inducing
peripheral immune tolerance and releasing a series of extracellular/angiogenesis signaling molecules
leading to extensive modulation of the TME. This leads to the generation of highly aberrant tissue
functions. The modulated TME then converts into a pathological entity that continually evolves to aid
cancer progression and invasion [36]. The major components of the tumor microenvironment include
cancer-associated fibroblasts, immune cells and immune-suppressive cells that play a significant role
in tumor survival and metastasis (Table 1).
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Table 1. Mechanisms of tumor microenvironment modulation by Colorectal cancer-associated
extracellular vesicles.
Mechanisms Potential Role in Tumour Progression Ref.
A. Immune system regulation and
modulation
Reduced activation, cytotoxicity,
proliferation of Natural Killer (NK) cells
Increased secretion of immunosuppressive factors leads to
resistance in NK cells against inducing Fas- or
perforin-mediated apoptosis
Secretion of TGF-β1 disrupts IL-2 signaling to NK cells
Diminished expression of NKG2D receptor on NK cells
reduces recognition of malignant cells
[37–39]
Induction of CD4+ and CD8+apoptosis Activation of apoptosis-inducing ligands (Fas ligand,
TNF-related apoptosis-inducing ligand (TRAIL), galectin 9
etc. induces apoptosis of T cells
Inhibition of IL-2-dependent CD8+ T cell activation leads to
immunosuppression
[29,39,40]
Modulation of Tumour associated
macrophages (TAMs), Cancer associated
fibroblast (CAFs), epithelial and
endothelial target cells
Enhances release of cytokines/chemokines,
immunosuppressive factors, immune checkpoint
modulators, Tregs, myeloid-derived suppressor cells
(MDSCs) and type 2 helper (Th2) T cells that directly
suppress activated T cells
[41]
Increased secretion of myeloid derived
suppressor cell (MDSC) and T regulatory
cells (Treg)
Elevated levels of MDSCs and Tregs lead to secretion of
cytokines/chemokines and activation of signalling pathways
such as MAPK and NF-κB leading to immunosuppression
T regs suppress activation, proliferation and effector
functions of CD4+, CD8+ cells, NK cells, B cells and
dendritic cells (DC)
Increased Treg levels initiate angiogenesis and increased
vascularization
[39,42,43]
Alteration of complement system Increased expression of surface molecules CD55, CD59, CD9
signals leads to inhibition of complement-mediated lysis
[44]
Modulation of mesenchymal stem cells Leads to atypical morphology/spheroid formation that
induces acidic microenvironment and leads to
immuno-suppression
Spheroids activate NOTCH3/Wnt signalling pathways that
facilitates drug resistance
[40,45]
Enhanced release of reactive oxygen
species and Nitric oxides
Leads to induction of hypoxic environment facilitating
immuno-suppression
[46]
Interaction of miRNA with mRNA
transcripts
Leads to mRNA deregulation converting them into
oncogenes or tumor suppressors
Increases the proliferation of fibroblasts, epithelial and
endothelial target cells leading to immune suppression and
induction of drug resistance
[47,48]
B. Metastasis
Expression of adhesion
molecules/integrins
Facilitates metastatic organotropism/establishment of
pre-metastatic niche via adhesion with specific resident
cells/fibroblasts/epithelial cells for invasion
[49,50]
Upregulation of cytoskeleton
re-modelling
Secretion of extracellular matrix
associated proteins
Induction of epithelial-mesenchymal
transition (EMT)
Leads to formation of invadopodia for increased motility
Causes vascular leakiness
Releases EVs-bound proteins for enhanced migration of
tumor cells
[51,52]
Transfer of miRNAs to immune cells Leads to macrophages skewing towards pro-inflammatory
phenotype facilitating colonization and invasiveness
[30]
Modulation of tumour microenvironment Leads to macrophage infiltration, activation of Src
phosphorylation signaling pathways, release of
pro-inflammatory cytokines and chemokines for
extracellular matrix re-modelling
CAFs induce motile and proteolytic activity in tumor cells
for enhanced invasiveness
[53]
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Table 1. Cont.
Mechanisms Potential Role in Tumour Progression Ref.
Modulation of mesenchymal stem cells Leads to atypical morphology/spheroids formation inducing
immuno-suppression and proliferation/invasion
[30]
C. Drug Resistance
Sequestering, expulsion of cytotoxic drugs EVs extrude cytotoxic drugs
EVs compete with anti-tumor drugs for their binding sites
leading to drug resistance
[54,55]
Induction of Stem-ness in tumor cells Induces atypical morphology and spheroid formation
leading to immuno-suppression and expression of drug
resistant phenotypes
Modulation of CAFs by cancer stem cells leads to increased
Wnt activity in cancer stem cells conferring drug resistance
[56,57]
Activation of signalling pathways STAT1 dependent response and NOTCH3 signalling
pathway leads to decreased cell apoptosis and
chemo-resistance
[57,58]
Lateral transfer of drug resistant
phenotypes via miRNAs
miRNAs carrying drug resistant phenotypes confer chemo
resistance by transfer of resistant genes to sensitive recipient
tumor cells
[16]
The normal colon comprises of a stromal population that provides a physical architecture for
uniform functioning of the colonic tissue. The main constituent of the colonic stroma includes
fibroblasts that not only form the structural framework of tissues through their secretion of extracellular
matrix constituents (ECM) but also aids in synthesis, deposition, and homeostasis of the basement
membrane components thus maintaining tissue function [59]. Keeping the significance of colonic tissue
integrity as a critical parameter for normal functioning of the colon, tumor cells aim to modulate and
transform/differentiate fibroblasts into dysregulated cell types, known as cancer-associated fibroblasts
(CAF) [60]. Once differentiated, CAF’s, release large number of growth factors, hormones and cytokines
such as osteopontin (OPN), hepatocyte growth factors (HGF), epidermal growth factors (EGF), IGF
1 and 2, FGF 2 and 7, PGE-2, vascular endothelial growth factor (VEGF), stromal derived factor-1
(SDF-1), macrophage migration inhibitory factor (MIF), vitronectin, interleukins, microRNA (miRNA)
that modulate immune responses to directly and indirectly support tumorigenesis. Furthermore,
CAF’s also contribute to the initiation of motile and proteolytic phenotype in tumor cells by inducing
epithelial-mesenchymal transition (EMT) that potentiates invasiveness and metastasis [60]. In CRC,
CAFs are the most abundant stromal cells involved in modulation of the TME into a highly vascularized
environment thus promoting tumor progression and leading to poor clinical outcomes [61].
In addition to CAFs, the CRC landscape is infiltrated by a variety of innate and adaptive immune
cells, including lymphocytes (T cells, B cells, natural killer cells), monocytes, macrophages, dendritic
cells, granulocytes (neutrophils, basophils, eosinophils, mast cells), T regulatory cells (Tregs) and
myeloid-derived suppressor cells (MDSC) [62]. Of these immune cells, macrophages are considered to
play an important role in immune defense by regulating T-and B-lymphocyte activation and proliferation.
In CRC, release of chemokines, cytokines and growth/angiogenic factors such as monocyte chemotactic
protein-1 (CCL2), CCL3, CCL4, CCL5 (RANTES), CCL22 (macrophage-derived chemokine), CXC
chemokines (CXCL8), Colony-stimulating factor-1 (CSF1) etc. polarizes these macrophages to the
tumor tissue converting them into highly specialized cells known as tumor-associated macrophages
(TAMs) [63]. These TAMs, in turn, facilitate modulation of tumor microenvironment by initiating
an immunosuppressive entity through the release of cytokines/chemokines and immunosuppressive
factors such as IL-10, TGF-β, immune checkpoint modulators (Programmed death-1/programmed
death ligand 1), Tregs, myeloid-derived suppressor cells (MDSCs) and type 2 helper (Th2) T cells. These
released factors directly suppress activated T cells leading to enhanced tumor growth and survival [41].
In the tumor microenvironment, the most widely known immune-suppressive cells include
myeloid-derived suppressor cells (MDSC) and the T regulatory cells (Tregs). The MDSC is functionally
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defined as immunosuppressive, immature myeloid cells that significantly contribute to tumor
progression via angiogenesis and metastasis [64]. Activation of MDSC during tumorigenesis occurs via
the release of factors either by activated T cells or tumor stromal cells including COX2, prostaglandins,
IL-6, GM-CSF, VEGF, IFN-γ, IL-13, TGF-β. These factors stimulate myelopoiesis leading to upregulation
of STAT3 target genes (B-cell lymphoma XL (BCL-XL), cyclin D1, MYC, survivin, S100 calcium binding
protein A8 (S100A8) and S100A9) and signaling pathways (STAT6, STAT1, and NF-κB) allowing
infiltration of MDSC to tumor sites [65]. Once infiltrated, MDSC exerts their immunosuppressive
action by modulating/inhibiting mechanisms of immune-surveillance including antigen presentation
by dendritic cells (DCs), T cell activation, M1 macrophage polarization and NK cell cytotoxicity [66].
In CRC, metastasis and tumor growth has been associated with elevated levels of circulating and tumor
localized MDSCs that release cytokine/chemokine/ protein within the tumor microenvironment (CCL2,
CCL15, S100A8, and S100A9) and activate signaling pathways such as MAPK and NF-κB for sustained
growth [67,68].
Another set of immune-suppressive cells in the tumor microenvironment includes Tregs
which have diverse effects on tumorigenesis. Tregs mainly exert immunosuppression by secreting
immune-suppressive cytokines such as IL-10, TGF-β, and IL-35 and affecting cytotoxic T cell function
by inhibiting cytolytic granule release. Furthermore, Tregs suppress the activation, proliferation and
effector functions of CD4+ and CD8+ cells, NK cells, B cells, maturation of dendritic cells (DC) as
well as inhibition of co-stimulatory molecules In addition to exerting immunosuppressive activity,
infiltration of Tregs can initiate angiogenesis and increased vascularization leading to poor outcomes
in CRC patients [43].
In addition to these immune suppressive cells, there are a variety of other immune cell populations
found in the tumor microenvironment such as dendritic cells, monocytes, neutrophils, mast cells,
NK cells, CD4, CD8 cells, B cells that play diverse roles in promoting tumorigenesis in CRC via
degranulation, release of pro-angiogenic factors, growth stimulatory factors (VEGF, FGF2, TNF-α),
angiopoitin-1 and tryptase, granzyme B, perforin and upregulation of MHC class 1 and co-stimulatory
ligands leading to tumor progression and proliferation [61].
4. Role of EVs in Immune System Regulation and Modulation in CRC
EVs have been reported to regulate the immune system by activation of antigen-specific CD4+ or
CD8+ T cell responses through antigen presentation via direct and indirect pathways (Figure 1). In the
direct pathway, either the MHC class II peptide complexes, co-stimulatory (Tim1/4 for B cells) and
adhesion molecules (ICAM-1) on the EV surface interact with corresponding T cell receptor to activate
CD4+ or CD8+ cells or the EVs directly activate macrophages, neutrophils, natural killer cells, and APCs
subsequently activating CD4+ or CD8+ T cells. In indirect pathway, either the EVs are internalized
by antigen presenting cells (APCs), or they bind to the APCs via integrins and intercellular adhesion
molecules leading to antigen presentation and activation of CD4+ or CD8+ T cells [42,69]. Due to the
intrinsic ability of EVs to regulate the T cells, cancer-associated EVs can facilitate immune modulation
and suppression within the tumor microenvironment to promote tumor progression. In CRC, immune
suppression, immune escape and drug resistance within the microenvironment is mediated by CRC
EVs utilizing various interaction such as (a) remodeling of tumor-stromal interactions, (b) transfer of
genetic materials including proteins, mRNA and non-coding RNAs (miRNA, long coding RNA, etc.)
and (c) release of MDSC and immune suppressive molecules [70].
Remodeling of tumor-stromal interactions in CRC occurs via transfer of stromal EVs in colonic
mesenchymal stem cells (cMSC). This leads to major aberrations in cMSC including the formation of
spheroids, atypical morphology and increased vacuolar H+-ATPase redistribution that induces an
acidic microenvironment. All these remodeling associated changes exert an immune suppressive (due
to acidic environment) and immune-privileged (due to spheroids) conditioned environment for the
CRC cells allowing them to proliferate, invade and metastasize [30]. Furthermore, spheroid formation
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initiates NOTCH3/Wnt signaling pathways that also confer drug resistance associated properties to
the CRC cells [45].
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Figure 1. Re-modeling of tumor microenvironment by EVs in RC. EVs are associated with inducing
re-modelling of the tu or icroenvironment to promote tumor progression via mechanisms including;
(a) differentiation of macrophages, stromal fibroblasts etc., (b) secretion of cytokines/chemokines to
induce expansion of regulatory cells such as Tregs, myeloid derived secreted cells (MDSCs), (c) reducing
proliferation of natural killer cells (NK cells), (d) inducing apoptosis of cytotoxic T-cell (CD8+),
(e) damaging extracellular matrix to promote cell migration and invasion, (f) inducing phenotypic
changes, (g) secreting non-coding RNAs, (h) promoting drug resistance.
Another way of tumor-stromal interactions re-modeling in CRC is via EV-mediated transfer of
non-coding RNAs (Table 2). Transfer of non-coding RNAs plays a critical role in inducing aberrant
behaviors in tumors and modulation of tumor microenvironment functions. The main non-coding
RNAs involved in immune modulation in CRC includes miRNAs (miR210, miR193a, miR19a, etc.),
long coding RNA (MAGEA3, CRNDE-h) and circular RNA (circ-KLDHC10, circRTN4, etc.). The main
mechanism of action is through the interaction of non-coding RNAs with their mRNA transcripts
leading to deregulation of mRNA and converting them into oncogenes or tumor suppressors that
promote tumor progression and metastasis. Furthermore, these deregulated mRNAs also influence
the tumor microenvironment by increasing the proliferation of fibroblasts, epithelial and endothelial
target cells within the microenvironment leading to immune suppression and induction of drug
resistance [47,48].
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Table 2. Key targets and role of EV derived non-coding RNAs in colorectal cancer.
micro-RNA/
lncRNA/Proteins
Level Key Targets Role in CRC Reference
miR-17-92a upregulated TSP-1, CTGF,
PTEN,BCL2L11,E2F1,E2F2,
E2F3,TGFBR2,CDKN1A,BIM
Angiogenesis, proliferation,
metastasis
[71–73]
miR-18a upregulated ATM, mTORC1, hnRNP
A1,CDC42
Cell proliferation, migration [71,73–75]
miR-92a upregulated PTEN cell proliferation, migration,
invasion, prognosis
[76]
miR-218 downregulated BMI-1 cell proliferation, apoptosis, cell
cycle arrest
[77]
miR-31 upregulated CDKN2B, RASA1,FIH-1,
RhoBTB1
Cell proliferation, invasion,
migration, tumor growth,
prognosis
[73,78,79]
miR-95 upregulated SNX1 cell proliferation, tumor growth [80]
miR-29a upregulated KLF4 cell invasion, metastasis,
prognosis
[81,82]
miR-96 upregulated TP53INP1, FOXO1, FOX03a cell proliferation [83]
miR-214 downregulated FGFR1 cell proliferation, migration,
invasion
[84]
miR-100 downregulated RAP1B cell proliferation, invasion,
apoptosis
[79]
miR-194 downregulated PDK1, AKT2, XIAP,
MAP4K4
Cell proliferation, apoptosis,
migration, prognosis
[79]
miR-206 downregulated NOTCH3 cell proliferation, migration,
apoptosis, cell cycle arrest
[85]
miR-103 upregulated DICER, PTEN cell proliferation, migration,
tumor growth
[86]
miR-143 upregulated KRAS, ERK5, MACC1, HK2,
IGF1R, DNMT3A
Cell proliferation, metastasis [73,74]
miR-196b upregulated FAS cell apoptosis [87]
miR-148a upregulated BCL2 Cell proliferation [73,88]
miR-375 downregulated PIK3CA cell proliferation, cell cycle arrest,
tumor growth
[89]
miR-181a upregulated WIF-1, PTEN cell proliferation, migration,
invasion, prognosis, tumor
growth
[90,91]
miR-21 upregulated PDCD4, CCL20, Cdc25A,
TGFBR2, PTEN, RHOB,
RASA1
Cell proliferation, migration,
invasion, metastasis, stemness
[73,92]
miR-155 upregulated CLDN1 Cell proliferation, migration,
invasion, chemoresistance
[73]
miR-145 downregulated FASCIN-1 Cell proliferation, invasion,
tumor growth
[93]
miR-32 upregulated PTEN cell proliferation, migration,
invasion, apoptosis
[94]
miR-378 downregulated VIMENTIN cell proliferation, invasion,
tumor growth, prognosis
[95]
miR-124 downregulated STAT3 cell proliferation, apoptosis,
tumor growth, prognosis
[96]
miR-126 downregulated VEGF, IRS-1, CXCR4 cell proliferation, migration,
invasion, prognosis
[97–100]
miR-10b upregulated Syndecan-1 tumor suppression, invasion [101]
miR-375 upregulated Bcl-2 apoptosis, tumor suppression [102]
miRNA-210 upregulated VMP1 tumor growth, metastasis,
migration, invasion
[103,104]
miR-200c upregulated ZEB2 and SNAI, PTEN migration, metastasis, invasion,
tumor growth
[102,105]
miR-141 upregulated ZEB2 and SNAI, MAP2K4 migration, metastasis, cell
proliferation
[102,106]
miR-429 upregulated ZEB2 and SNAI, HOXA5 migration, metastasis, tumor
growth
[102,107]
miRNA-19a upregulated TIA1 Cell proliferation and migration [108,109]
let-7a upregulated NIRF Cell proliferation, tumorigenesis [108,110]
miR-1246 upregulated CycG2, CCNG2 differentiation, invasion,
metastasis, chemoresistance
[108,111]
miR-150 upregulated iASPP tumor growth, metastasis, cell
proliferation
[108,112]
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Table 2. Cont.
micro-RNA/
lncRNA/Proteins
Level Key Targets Role in CRC Reference
miR-21 upregulated TIMP3, ANP32A, THRB,
PELI1, SPRY 1/2, PDCD4,
FASL, PTEN, BCL2, PPARA,
HNRPK, TP63
Cell proliferation, invasion,
metastasis, apoptosis
[108,113]
miR-223 upregulated STMN-1 cell proliferation, migration,
invasion
[108,114,115]
miR-23a upregulated MTSS1 migration, metastasis, cell
migration, invasion
[108,116]
miR-193a upregulated Caprin1 tumor progression [117]
∆Np73 upregulated Cell proliferation, drug resistance [118]
CRNDE-h upregulated DUSP5/CDKN1A proliferation, apoptosis,
metastasis
[119,120]
MAGEA3 upregulated cell growth, differentiation,
invasion
[121,122]
The CRC EVs mediate immunosuppressive circuit and release of MDSCs by interacting with
monocytes through membrane fusion and altering their differentiation towards transforming growth
factor (TGF-β) secreting myeloid suppressor cells. These transformed myeloid cells exert inhibitory
effects on T lymphocyte proliferation and effector functions by expressing CD14 on their surface with
lack of co-stimulatory molecule up-regulation and reduced expression of HLA class II. This facilitates
transformed myeloid cells to spontaneously secrete TGF-β—a key cell for immune suppression [123].
Furthermore, CRC EVs also promote immunosuppressive activity by autocrine stimulation of the
IL-6/STAT3 pathway leading to immune suppression via secretion of MDSC population thus facilitating
tumor growth. In addition to this, the CRC EVs mediate hyper activation of Wnt 4/β-catenin signaling
due to hypoxic microenvironment, leading to enhanced proliferation and migration of endothelial
cells. This accelerates tumor growth and promotes angiogenesis [61].
It is evident that the CRC EVs are involved in modulation of the tumor microenvironment and
secretion of immune suppressive cells to facilitate proliferation, angiogenesis, invasion, and metastasis
in colorectal cancer.
5. Role of EVs in the Induction of Metastasis in CRC
EVs, through their content specific molecules, have been identified as critical players in tumor
metastasis, transformation, and invasion (Table 1). Studies have reported that EVs induce invasive and
metastatic abilities in tumor cells via interactions with the cytoskeleton, extracellular matrix, transfer
of non-coding RNAs and immune regulation [124,125].
Studies on cytoskeleton remodeling have reported that cancer cells are capable of forming actin
rich protrusions known as invadopodia to initiate invasiveness. Furthermore, EVs have been reported
to be associated with these invadopodia to facilitate ECM degradation and metastasis. The main
mechanism of these invadopodia is to dock to the ECM, then recruit EVs to their plasma membrane
allowing them to secrete matrix metalloproteinases that initiate degradation of the ECM and facilitate
invasiveness [124]. On the other hand, it has been reported that mature invadopodia have the capability
to facilitate further invasiveness by inducing invadopodia formation in non-invasive cells thus allowing
enhanced secretion of proteinases via EVs and increasing invasiveness and metastatic potential of
cancer cells [124]. In CRC, invadopodia formation with upregulation and secretion of several matrix
metalloproteinases (MMP) have been associated with invasiveness and metastasis indicating critical
role of cytoskeleton remodeling and associated EVs in promoting metastasis [126].
EVs also have the capability to interact with ECM directly to transfer cargoes that lead to ECM
degradation. E.g., exosomes expressing high levels of CD96c and CD44 are capable of binding to
the hyaluronic acid of the ECM leading to enhanced degradation and invasiveness [125]. Similarly,
a study on CRC cell lines has reported that fibroblasts activated by late stage cancer-exosomes are
capable of upregulating pro-invasive regulators of membrane protrusion (PDLIM1, MYO1B) and
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matrix-remodeling proteins (MMP11, EMMPRIN, ADAM10) leading to increased invasiveness via
ECM [127]. Furthermore, a study on CRC patients has documented upregulation of MMP9, cathepsin
B (CTSB), and A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13)
in serum purified exosomes of CRC patients. As these MMPs are critical for ECM degradation
as well enhancement of immune and signaling pathways such as TGF-β/Smad pathway, their
upregulation indicates that the CRC exosomes play a vital role in promotion of adhesion as well as
triggering of signaling pathways/inflammatory responses in cancer cells for metastasis and increased
invasiveness [128].
In addition to these, an interesting feature of EVs is their ability to establish a pre-metastatic
niche—a phenomenon whereby the primary tumor can promote its metastasis by recruiting immune
cells to distant organs to establish a supportive metastatic environment [129]. In CRC, the liver
has been reported to be the main target of metastatic organotrophism for the establishment of the
pre-metastatic niche. It is reported that the establishment of the pre-metastatic niche is a critical step in
the initiation of metastasis and is mediated by many factors. Firstly, the expression of integrins (cell
receptor adhesion proteins) such as ITGα6β4/ITGα6β1 by CRC EVs serves as favorable determinants
of metastatic organotropism due to their adhesion with specific resident cells and fibroblasts/epithelial
cells conferring invasive properties to the CRC cells [49,50]. Secondly, a transcriptome analysis study
on CRC mediated EVs and their effect on liver organotropism have shown that immune modulation
within the tumor microenvironment can play an important role in proliferation and metastasis. Major
players described in immune modulation and subsequent extracellular matrix remodeling includes
macrophage infiltration, activation of Src phosphorylation signaling pathways (S100A families),
the release of pro-inflammatory cytokines and chemokines (IL-6, TNF-α, CCL8, CXCL1, CXCL13,
TGF-β) [53]. Thirdly, immune modulation in the tumor microenvironment to facilitate metastasis
by CRC EVs is also reported to be a result of exposure of cMSC to EV components. This leads to
the spheroid formation which allows functional changes in the microenvironment leading to higher
proliferation, migration, and invasion [30]. In addition to these, another mechanism associated with
migration and invasion as well as conditioning a permissive pre-metastatic niche for colonization
in CRC cells is associated with the transfer of non-coding RNAs, in particular, miR17-92a, miR-210,
miR-19a, miR-193a, etc. These non-coding RNAs serve to regulate macrophages skewing them towards
a pro-inflammatory phenotype thus facilitating colonization and initiating invasive properties in
these cells [30]. Furthermore, proteomics analysis has shown that upregulation of a number of CRC
mediated proteins such as SERPINA1, SERPINF2 and MMP9 play an important role in the extracellular
matrix and cytoskeleton remodeling leading to vascular leakiness and tumor-promoting migration and
invasiveness [51]. Therefore, it is concluded that a large number of CRC EV-associated non-coding RNA,
proteins and inflammatory molecules serve as key players in tumor proliferation, the establishment of
pre-metastatic niche, invasion, and metastasis.
6. Role of EVs in Drug Resistance in CRC
Drug resistance in CRC has also been attributed to the EVs through their content specific cargoes.
The main mechanism of drug resistance via CRC EVs is through sequestering of cytotoxic drugs in
their vesicles and subsequent expulsion [54]. Exosomes do this by sequestration of cytotoxic drugs in
the intracellular vesicles and subsequent expulsion, to negate drug effect within the cells [130,131].
A study in melanoma, adenocarcinoma and lymphoma cells reported that drugs such as cisplatin,
5-flurouracil and vinblastin were confiscated in the endosomal compartment of these cancer cells [132].
Similarly, exosomes secreted from cisplatin resistant ovarian cancer cells showed 2.6-fold higher drug
concentration indicating the role of exosomes in extrusion of cytotoxic drugs. On the other hand, rate
of exosome secretion and its composition was found to be altered in cancer cells exposed to radiation
indicating their role in radiotherapy resistance as well [133]. Furthermore, EVs have been documented
to carry drug efflux pumps such as P-glycoprotein 1 also known as multidrug resistance protein 1
(MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1), ABCG2 or ABCA3 that facilitate the
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transfer of drug resistance to recipient cancer cells [134]. Several studies on cancer models of prostate,
ovarian, leukemia and osteosarcoma have reported the role of EVs carrying these drug efflux pumps in
the transfer of multidrug resistance to sensitive cells indicating this as one of the mechanisms utilized
by EVs in conferring drug resistance in recipient cells [135–138]. It has been documented that EVs are
capable of transferring these MDR proteins, either as a fully functional protein or as mRNA encoding
for the protein, by direct interaction with the recipient cancer cell [138].
Another common mechanism of drug resistance documented for EVs is via transfer of miRNAs
that cause alteration of EMT mediated signaling pathways such as TGF-β/SMAD and targeting mRNA’s
that subsequently lead to up regulation of drug-efflux pumps [139]. In a study on colorectal cell lines,
it was observed that CRC exosomes are capable of activating Wnt/β-catenin pathway by promoting
the stabilization and nuclear translocation of β-catenin leading to 5-FU and oxaliplatin resistance [56].
On the other hand, EVs can also induce drug resistance via targeting of apoptosis regulators such
as Bcl-2/BAX signaling pathways that transfer drug resistance in recipient cells via promotion of
anti-apoptotic pathways [140]. Furthermore, reports on augmentation of drug resistance pathways
via modulation of apoptotic pathways have been described in stromal and breast cancer cells. In this
study it was observed that transfer of non-coding RNA via EVs to cancer cells lead to activation of
the pattern recognition receptor RIG-I that in turn activated STAT1-dependent anti-viral signaling.
Simultaneously, the stromal cells induced activation of NOTCH3 on breast cancer cells. This paracrine
anti-viral and juxtacrine NOTCH3 pathways converge, leading to facilitation of STAT1 transcriptional
responses to NOTCH3 thus expanding therapy resistant breast cancer cells [58]. Similarly, in CRC cell
lines, EVs have been associated with cetuximab resistance via down regulation of PTEN leading to
increased phosphorylation of AKT levels [141]. Many studies have documented another mechanism of
drug resistance by EVs. It has been reported that as a result of treatment such as hypoxia or radiation,
levels of TNF-α, TGF-β, PDGF, CXCL12, MMP, and HIF are elevated within the tumor associated
EVs. These EVs carrying cancer stem cell features, when transferred to recipient cancer cells induce
modulation of various signaling molecules such as Hedgehog, Wnt, β-catenin etc., thus enhancing
resistance to cancer therapies [142]. On the other hand, chemoresistance in CRC is also attributed to
the ability of miRNAs to promote stemness in cancer stem cells (CSC) leading to atypical morphology
and spheroid formation [57].
A recent study on EVs derived from both serum and tissue of CRC patients was found to be
enriched in miR-196b-5p as compared to the healthy control subjects. Comparison in survival analysis
indicated that CRC patients having high levels of miR-196b-5p had poor survival. The main reason
for this was associated with targeting of immune regulators, SOCS1 and SOCS3, of STAT3 signaling
pathway leading to activation of STAT3 signaling thus promoting stemness and chemoresistance
against 5-fluorouracil [57]. Further studies on this aspect have reported that certain tumor markers such
as CK19, TAG72, and CA125 are expressed by EVs in chemotherapy-resistant and highly metastatic
CRC cells indicating EVs can be utilized as chemoresistance markers in CRC [143].
7. EVs as Potential Source of Biomarkers in CRC
In CRC, it is well established now with many studies showing promising results that EVs can
serve as potential source of biomarkers of response, recurrence or drug-resistance (Figure 2). Elevated
levels of EV cargoes, especially miRNAs, lncRNA, circ. RNAs, in biological samples of CRC patients,
have been linked to the high expression of cancer antigens and shorter survival [144]. The most
valuable EV derived candidates in CRC diagnostics include miRNAs like miR-21, miR-29a, miR-92a,
miR-100, miR-200, miR-223, miR-1229 [51,117,145–147]. Studies have reported that high expression
of miRNAs, such as miR-125a-3p and miR21 can be useful for diagnosing a patient at an early stage
or before undergoing any treatments [148]. Similarly, EVs like miR-19a and miR-4772-3p have been
reported in high quantities in human serum samples and can serve as a potential prognostic marker
for disease recurrence in CRC [149].
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Figure 2. EVs as a potential source of biomarkers and therapeutic targets in RC: EVs are s creted in
various body fluids including plasma, serum, faeces ascites fluid etc. [150]. The detecti n of cancer
associated EVs and its cargoes including miRNA, lncRNA, circ. RNA and several proteins can be used
as potential source of biomarkers/prognostic markers in RC. In cancer therapeutics, engineered EVs
can be used for potential vaccine development and induction of immuno-modulatory mechanisms to
promote anti-tumor response such as depletion of Tregs and MDSCs, increasing proliferation of NK
cells, monitoring of cytokine/chemokines and utilizing EV cargoes as nanoparticles for drug delivery.
Furthermore, analysis of serum samples of CRC patients have shown the presence of collapsing
response mediator protein, along with EVs, and these have been directly correlated to poor survival
rates [151–153]. On the other hand, proteomic analyses of EVs from ascites of CRC patients have
reported the expression of endosomal markers such as ephrin-B1 and cadherin-17 [154].
A recent study conducted to determine whether glypican 1 (GPC1) positive EVs in plasma samples
could be used as a potential biomarker for CRC has shown interesting results. Higher levels of GPC1
in CRC patients were observed before surgery as compared to normal healthy controls. In addition to
GPC1, non-coding RNAs, miR-96-5p and miR-149, were also identified as potential candidates for
diagnosis of CRC [155].
Similar to miRNAs, long coding RNAs (lncRNAs) secreted by EVs are also being investigated
as a biomarker in CRC [52]. Studies on bio-informatics analysis have identified Bladder Cancer
Associated Transcript 1 (BLACAT1) and lncRNAs (LOC344887, LINC00675, DPP10-AS1, HAGLR) to
be downregulated in CRC patients as compared to healthy volunteers [156]. Similarly, another study
has identified mRNAs (KRTAP5-4, MAGEA3) and lncRNA (BCAR4) as potential candidates for the
detection of CRC [121]. Similarly, circular RNAs were found to be downregulated in HCT116 and KRAS
mutant cells compared to cells bearing wild type KRAS [157] suggesting its use as a biomarker in the
screening of CRC patients bearing KRAS mutation. On the other hand, a new cirRNA (cir-KLDHC10)
was significantly upregulated in CRC-derived EVs in comparison to EVs of healthy participants
indicating its potential as a biomarker [158].
The main topic of interest now is to utilize these EVs for drug delivery and therapeutics. Studies
have shown that engineering of EVs can facilitate delivery of drug and therapeutic nucleic acids
precisely. E.g., HCT 116 cells engineered to express miR-379 within EVs, when transferred to recipient
cancer, decreased proliferation and migration rate of CRC cells [159]. Similarly, a study conducted
in a colon adenocarcinoma mouse model reported that EVs delivering doxorubicin were able to
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reduce tumor size more efficiently in comparison to free or liposome-delivered doxorubicin [160]. This
indicates that EVs not only play a significant role in the CRC tumorigenesis process but also serve as
a potential source of biomarkers or therapeutic targets, that can be modelled into a useful tool for the
clinical management of CRC patients.
8. Challenges for Using EVs as Potential Source of Biomarkers in CRC
The role of EVs in the modulation of the tumor microenvironment, metastasis and drug resistance
with promising evidence on their utility as potential source of biomarkers in CRC has been explored
in detail in this review. However, with various studies exploring the translational potential of EVs,
a number of limitations and challenges need to be addressed in order to prevent undesirable effects with
its application. Firstly, an efficient way of EVs classification has not been achieved as yet. As molecular
profiles of EVs have been observed to be different within the same pathogenesis, it is suggested that until
a robust method of EVs classification based on protein profiling, nucleic acid profiling, size or affinity
are described, its use as potential source of biomarkers should be utilized with caution [51]. Secondly,
detection technologies for distinguishing EVs have not been properly standardized [17]. The main
methods utilized for EV isolation include ultracentrifugation, microfiltration, gel filtration, precipitation
with polyethylene glycol, protamine, and sodium acetate [22]. Recently, microfluidic technologies
for isolation of EV population based on highly specific interactions with the molecules exposed on
the EV surface have also bene defined. However, due to technical hurdles in each of these isolation
methods such as complexity, loss of sample, failure to separate large vesicles with similar sedimentation
rates, contamination with viral particles, deformation of vesicles, small quantity of exosomal proteins,
co-isolation of large protein aggregates/lipoproteins, poor reproducibility, contamination with non-EV
proteins, aggregation in multi-vesicles and difficulties with detachment of molecules/analysis of intact
vesicles have been reported, it is critical that standardization with robust internal and external quality
control assessments need to be in place in order to validate their isolation so that they can be utilized
as potential source of biomarkers [22]. Thirdly, large randomized control trials/translational studies
need to be performed so that validation of their efficient therapeutic potential can be determined [161].
This is critical as EVs carry signature proteins from the host and therefore their application in non-host
patients may have immunogenic implications [162]. Therefore, with standardized detection/isolation
techniques and profiling methods along with robust clinical trials in place, the utility of EVs in
CRC and other cancer could be highly valuable for therapeutic implications and as potential source
of biomarkers.
9. Conclusions
Evidence documented to date indicates that EVs are capable of inducing various modulations
in the tumor microenvironment leading to metastasis, tumor cell proliferation, and drug resistance.
Utilizing this knowledge, it is possible to understand the dynamics of EVs in immune modulation with
CRC therapeutic utility. This strategy would include engineering EVs for vaccine development and
induction of immuno-modulatory mechanisms to promote anti-tumor responses, such as depletion
of Tregs and MDSCs, increasing proliferation of NK cells, monitoring of cytokine/chemokines and
utilizing EV cargoes as nanoparticles for drug delivery. Furthermore, EVs can also serve as novel
non-invasive markers that can be used as diagnostic tools for screening and management of CRC.
However, it is recommended that the data on CRC derived EVs should be extrapolated to extensive
large, randomized clinical trials to further validate the published data. Furthermore, translational
studies need to be initiated to ascertain the therapeutic potential and utility of EVs. Future perspectives
should be EV-based immunotherapy, EVs as delivery vectors, or EVs as therapeutic targets in CRC that
will help in cancer management.
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CRC colorectal cancer
CEA carcinoembryonic antigen
EVs extracellular vehicles
MVBs multivesicular bodies
miRNAs micro-RNAs
UTR untranslated region
GOFs gain of oncogenic functions
FU 5-fluorouracil
TME tumor microenvironment
CAFS cancer-associated fibroblasts
ECM extracellular matrix constituents
TGF β transforming growth factor β
PDGF platelet derive growth factor
MCP1 monocyte chemotactic protein 1
IGF insulin-like growth factor
FGF-2 fibroblast growth factor 2
PGE prostaglandin E
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TREG–T regulatory cells
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